Rheumatoid nodule, multiple sites — subcutaneous or deep-tissue nodules associated with rheumatoid arthritis occurring at more than one anatomical location simultaneously.
Verified May 8, 2026 · 6 sources ↓
- Status
- Billable
- Chapter
- 13
- Related CPT
- 9
- Region
- Multi-region
Documentation tips
What should appear in the chart to support M06.39.
Source · Editorial brief grounded in 6 cited references ↓
- Name each nodule location explicitly (e.g., right olecranon, left Achilles tendon) — 'multiple sites' must be supported by at least two distinct documented locations.
- Distinguish the nodule finding from the underlying RA diagnosis; document both the rheumatoid nodules (M06.39) and the RA type (e.g., M05.79 or M06.09) when both are managed in the encounter.
- Record rheumatoid factor status and anti-CCP results in the note — this determines which RA code pairs with M06.39 and prevents audit flags from undifferentiated RA coding.
- Document nodule characteristics (size, consistency, mobility, tenderness) to support clinical necessity for imaging, biopsy, or surgical excision if performed.
- If a nodule has been biopsied or excised, link the pathology result confirming rheumatoid nodule histology back to M06.39 in the problem list.
Related CPT procedures
Procedure codes commonly billed with M06.39. Linking the right diagnosis to the right procedure is what establishes medical necessity.
Source · CMS LCDs · AAOS specialty guidance · claims-pattern analysis
Common coding pitfalls
The recurring mistakes coders make with M06.39 and adjacent codes.
Source · Editorial brief grounded in CDC ICD-10-CM tabular guidance, AAOS coding references, and cited references ↓
- Coding M06.39 alone without a separate underlying RA code misses the full clinical picture and may reduce medical necessity support for biologics or DMARDs.
- Using M06.09 (seronegative RA, multiple sites) when the intent is to capture nodules — M06.09 codes the arthritis subtype, not the nodular manifestation.
- Defaulting to M06.9 (RA, unspecified) when the provider has explicitly documented rheumatoid nodules at multiple sites — that documentation supports the more specific M06.39.
- Assigning a single-site M06.3x code (e.g., M06.31 for shoulder) when nodules are present bilaterally or at multiple distinct regions — M06.39 is the correct choice for multi-site involvement.
- Confusing M06.39 with M06.89 (other specified rheumatoid arthritis, multiple sites) — M06.89 captures other specified RA variants, not the nodular complication specifically.
Clinical context
Source · Editorial summary grounded in 6 cited references ↓
M06.39 captures rheumatoid nodules documented at multiple sites in the same patient. Rheumatoid nodules are firm, non-tender subcutaneous masses that develop in the setting of rheumatoid arthritis, most commonly over pressure points such as the olecranon, finger joints, Achilles tendon, and sacrum. When nodules are present at two or more distinct locations, M06.39 is the correct code — not a single-site M06.3x code repeated per location.
This code sits within the M06.3 parent category (Rheumatoid nodule) and is used regardless of rheumatoid factor status — it describes the nodular manifestation, not the serological subtype of RA. If the underlying RA diagnosis itself requires separate coding (e.g., M05.79 for seropositive RA at multiple sites, or M06.09 for seronegative RA at multiple sites), code that separately and sequence it appropriately. M06.39 codes the nodular complication.
Do not confuse M06.39 with M06.09 (seronegative RA, multiple sites) or M06.89 (other specified rheumatoid arthritis, multiple sites). The key distinguishing factor is that M06.39 is specifically for the nodular manifestation — the physical finding of rheumatoid nodules — not for the arthritis diagnosis itself. Documentation must explicitly identify the lesions as rheumatoid nodules; a general RA note without nodule documentation does not support this code.
Sibling codes
Other billable codes under M06.3 (laterality / anatomic variants).
Frequently asked questions
Source · Generated from the editorial pipeline, verified against 6 cited references ↓
01Can M06.39 be used as a standalone code, or must it be paired with an RA diagnosis code?
02How many sites must be documented to use M06.39 instead of a single-site M06.3x code?
03Does rheumatoid factor status affect whether M06.39 is the right code?
04Is M06.39 appropriate when nodules are bilateral at the same joint (e.g., both elbows)?
05What CPT codes commonly pair with M06.39 in orthopedic or hand surgery encounters?
06Can M06.39 be used for nodular lesions found incidentally on imaging without a prior RA diagnosis on the chart?
07How does M06.39 interact with biologic therapy authorization?
Sources & references
Editorial content was developed using the following public sources. Last verified May 8, 2026.
- 01CDC ICD-10-CM Tabular List 2026 (FY2026, effective Oct 1, 2025)
- 02icd10data.comhttps://www.icd10data.com/ICD10CM/Codes/M00-M99/M05-M14/M06-/M06.39
- 03aapc.comhttps://www.aapc.com/codes/icd-10-codes/M06.39
- 04aapc.comhttps://www.aapc.com/codes/icd-10-codes/M06.3
- 05cms.govhttps://www.cms.gov/medicare/coding/icd10/downloads/icd10clinicalconceptsorthopedics1.pdf
- 06files.providernews.anthem.comhttps://files.providernews.anthem.com/4148/MULTI-ALL-CR-054648-24-NMROpt27_2643-Optum-D&C-Tps-Arthrtsldr_FINAL.pdf
Mira AI Scribe
The Mira AI Scribe captures nodule location(s) by name, laterality, size estimates, and any prior or current treatment (e.g., steroid injection, surgical excision) from the encounter narrative. It also pulls rheumatoid factor and anti-CCP status to pair M06.39 with the correct underlying RA code. This prevents the common error of collapsing a documented multi-site nodular complication into the nonspecific M06.9, which can trigger medical necessity denials for biologic therapy claims.
See how Mira captures M06.39 documentation